Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Reactive astrocytes as therapeutic targets for CNS disorders.
Tumefactive Multiple Sclerosis presenting as Acute Ischemic Stroke.
Quantitative assays for anti-aquaporin-4 antibody with subclass analysis in neuromyelitis optica.
The role of alemtuzumab in facilitating maintenance immunosuppression minimization following solid organ transplantation.
Stimulated PBMC-produced IFN-γ and TNF-α are associated with altered relapse risk in multiple sclerosis: results from a prospective cohort study.
Testing effects of glatiramer acetate and fingolimod in an infectious model of CNS immune surveillance.
Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple Sclerosis
Morphological differentiation of oligodendrocytes requires activation of Fyn tyrosine kinase.
Mountain View Pharmaceuticals receives European patent on potential long-acting drug for multiple sclerosis
Pharmacokinetic properties and metabolism of idebenone.
Cytokine switch and bystander suppression of autoimmune responses to multiple antigens in experimental autoimmune encephalomyelitis by a single recombinant T-cell receptor ligand.
Estimating Time to Disease Progression Comparing Transition Models and Survival Methods-An Analysis of Multiple Sclerosis Data.
CD8(+) T Cells Are Required For Glatiramer Acetate Therapy in Autoimmune Demyelinating Disease.
Active Biotech's partner Teva initiates a further clinical trial in multiple sclerosis
Self-reactive CD4(+) T cells activated during viral-induced demyelination do not prevent clinical recovery.
Human herpesvirus 6 and effectiveness of interferon β1b in multiple sclerosis patients.
Treatment of primary Sjögren syndrome with rituximab: a randomized trial.
CD56(bright) natural killer cells and response to daclizumab HYP in relapsing-remitting MS.
MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study.
IFNγ-stimulated dendritic cell exosomes as a potential therapeutic for remyelination.
Immunology 2014
BRAVO Study: Laquinimod Double Blind Placebo Controlled Study in RRMS Patients With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)
Treatment of acute transverse myelitis and its early complications.
Sanofi MS drug nears green light after pass-the-parcel marathon
Exercise and disease progression in multiple sclerosis: can exercise slow down the progression of multiple sclerosis?

Pages